Live Panel: Are you ready for the "Last Mile"?
Watch the recording of our panel discussion with experts from the World Health Organization, the Africa Medical Supplies Platform and the Brazilian Society of Infectious Disease to learn how to gear up for the next wave of COVID-19 vaccine shipments to the poorest nations of the world.

Whitepaper: False economy - reducing performance in virtual supply chains

By World Courier

Commercial shipments

When virtual supply chains put business continuity at risk

Excursions can significantly impact a developer's ability to recoup R&D costs, grow revenue, or even effectively treat patients.

The real difference between a 1% and a 0.1% excursion rate

Smaller drug developers are increasingly moving away from the traditional paths of creating their own infrastructure or partnering with a larger, vertically integrated pharma company. Instead, they are constructing virtual supply chains, comprising an ecosystem of globally dispersed partners responsible for manufacturing and distributing a product.
These virtual supply chains are often heavily siloed and localized, and usually prioritized by cost. From a logistics perspective, this presents two problems.

In this whitepaper, we examine why prioritizing cost over precision is simple false economy.

  • How to quantify the costs that stem from an excursion incident
  • Costs of excursions and logistical challenge prior and during the launch phases
  • Mitigating the risk of excursion and countering the effects of fragmentation